Literature DB >> 24634344

Intraoperative hemodialysis during liver transplantation: a decade of experience.

Mitra K Nadim1, Wanwarat Annanthapanyasut, Lea Matsuoka, Kari Appachu, Mark Boyajian, Lingyun Ji, Ashraf Sedra, Yuri S Genyk.   

Abstract

Liver transplantation (LT) for patients with renal dysfunction is frequently complicated by major fluid shifts, acidosis, and electrolyte and coagulation abnormalities. Continuous renal replacement therapy (CRRT) has been previously shown to ameliorate these problems. We describe the safety and clinical outcomes of intraoperative hemodialysis (IOHD) during LT for a group of patients with high Model for End-Stage Liver Disease (MELD) scores. We performed a retrospective study at our institution of patients who underwent IOHD from 2002 to 2012. Seven hundred thirty-seven patients underwent transplantation, and 32% received IOHD. The mean calculated MELD score was 37, with 38% having a MELD score ≥ 40. Preoperatively, 61% were in the intensive care unit, 19% were mechanically ventilated, 43% required vasopressor support, and 80% were on some form of renal replacement therapy at the time of transplantation, the majority being on CRRT. Patients on average received 35 U of blood products and 4.8 L of crystalloids without significant changes in hemodynamics or electrolytes. The average urine output was 450 ml, and the average amount of fluid removal with dialysis was 1.8 L. The 90-day patient and dialysis-free survival rates were 90% and 99%, respectively. One-year patient survival rates based on the pretransplant renal replacement status and the MELD status were not statistically different. This is the first large study to demonstrate the safety and feasibility of IOHD in a cohort of critically ill patients with high MELD scores undergoing LT with good patient and renal outcomes.
© 2014 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24634344     DOI: 10.1002/lt.23867

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  7 in total

Review 1.  Chronic Kidney Disease and Related Long-Term Complications After Liver Transplantation.

Authors:  Pratima Sharma; Khurram Bari
Journal:  Adv Chronic Kidney Dis       Date:  2015-09       Impact factor: 3.620

2.  Hemodynamics and vasoactive substance levels during renal congestion that occurs in the anhepatic phase of liver transplantation.

Authors:  Zhong-Xin Li; Man-Cai Wang; You-Cheng Zhang; Jie Mao; Mo Chen; Rui Ni; Feng-Xian Wei; Gen-Nian Wang; Ling-Yi Zhang
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

Review 3.  Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach.

Authors:  José Víctor Jiménez; Diego Luis Carrillo-Pérez; Rodrigo Rosado-Canto; Ignacio García-Juárez; Aldo Torre; David Kershenobich; Eduardo Carrillo-Maravilla
Journal:  Dig Dis Sci       Date:  2017-05-13       Impact factor: 3.199

4.  Association of HLA-DPA1 polymorphism with prolonged mechanical ventilation in patients undergoing liver transplantation.

Authors:  Eun Jung Kim; Min-Soo Kim; Myoung Soo Kim; Junhyun Nam; Seung Ho Choi
Journal:  Korean J Anesthesiol       Date:  2022-05-03

Review 5.  Liver Transplantation for Acute Liver Failure in Presence of Acute Kidney Injury.

Authors:  Narendra S Choudhary; Sanjiv Saigal; Neeraj Saraf; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2019-07-25

6.  Use of Renal Replacement Therapy May Influence Graft Outcomes following Liver Transplantation for Acute Liver Failure: A Propensity-Score Matched Population-Based Retrospective Cohort Study.

Authors:  Stephen R Knight; Gabriel C Oniscu; Luke Devey; Kenneth J Simpson; Stephen J Wigmore; Ewen M Harrison
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

7.  Intraoperative management of liver transplant recipients having severe renal dysfunction: results of 42 cases.

Authors:  Ha Yeon Kim; Ja Eun Lee; Justin S Ko; Mi Sook Gwak; Suk-Koo Lee; Gaab Soo Kim
Journal:  Ann Surg Treat Res       Date:  2018-06-26       Impact factor: 1.859

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.